SIGA Technologies, Inc. (OTCMKTS:SIGA) Director Paul G. Savas purchased 5,000 shares of the stock in a transaction dated Friday, November 16th. The shares were acquired at an average price of $5.58 per share, with a total value of $27,900.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of SIGA opened at $5.81 on Thursday. SIGA Technologies, Inc. has a 1 year low of $3.90 and a 1 year high of $8.47.
SIGA Technologies (OTCMKTS:SIGA) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported $4.71 earnings per share for the quarter. The business had revenue of $471.08 million for the quarter.
Separately, TheStreet upgraded SIGA Technologies from a “d-” rating to a “b” rating in a research note on Monday, November 26th.
About SIGA Technologies
SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).
Featured Story: Hedge Funds – Risk or Reward?
Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.